Zelminemab is an investigational monoclonal antibody designed to target and inhibit PACAP (pituitary adenylate cyclase-activating polypeptide), specifically its receptor PAC1. Its primary application lies in the potential treatment of neurodegenerative diseases, particularly Huntington’s disease. By blocking the PAC1 receptor, zelminemab aims to reduce excitotoxicity and neuroinflammation, which are key contributors to neuronal damage in Huntington’s disease. It has shown neuroprotective effects in preclinical models, helping preserve motor function and slow disease progression. Currently, zelminemab is being evaluated in clinical trials to assess its safety, tolerability, and efficacy in patients, representing a promising disease-modifying therapeutic approach rather than just symptom management.